Strong Australian delegation to BIO 2022 marks biotech’s global resilience


This year’s annual Australian delegation to the largest biotech event in the world will return in-person next week, led by AusBiotech, and demonstrates a strong industry with participation bouncing back to pre-pandemic sizes.

The Australian delegation will see a number of state governments, the Australian Ambassador to the United States, state ministers, over 170 companies and 300 delegates standing united.

AusBiotech leads the Australian contingent at the BIO International Convention 2022 in San Diego from 13-16 June, with the Australian Pavilion as the focal point. The delegation showcases Australian capabilities, promotes the strength of the Australian life sciences, and fosters global connections with its overseas counterparts.

The annual BIO International Convention hosted by the Biotechnology Innovation Organisation (BIO) and is the largest and most influential global event for the biotechnology industry. It draws more than 16,000 biotechnology and pharma leaders from over 3,000 companies and 67 countries and includes over 1,800 exhibitors and 800 speakers.

Lorraine Chiroiu, AusBiotech CEO will deliver a Global Innovation Hubs presentation on behalf of Australia, presenting Australia’s competitive advantage in the life sciences and sharing the top reasons to partner and invest in the Australian sector.

AusBiotech will host the Australian Wine Tasting Event this week, which continues to be a hallmark feature of the Australian Pavilion. The event draws BIO delegates from all corners of the exhibition hall and the globe to the national exhibit. The event has support from Agilex Biolabs and Medicines Australia.

The Pavilion features major supporters: MTPConnect, as well as state governments, including New South Wales Government and Investment NSW, South Australian Government, Victorian Government and Global Victoria, and Western Australian Government.

The mission to BIO continues to be closely aligned with AusBiotech’s strategic plan (2021-2024), which seeks to facilitate global engagement in strong established markets, including North America.

The Australian presence is one of the top ten largest international delegations, and it includes representatives from: 360Biolabs, Agilex Biolabs, Southern Star Research, Neuroscience Trials Australia, IQVIA, Medicines Australia, GenesisCare, Novotech, Avance, Clinials, Reece Pharmaceuticals, Alithia Life Sciences, Life Sciences Queensland, Greenlight Clinical, Evirma Technologies and CSIRO.

To find out more information on BIO 2022, click here.